Mavupharma
Pioneering non-nucleotide modulators of the STING pathway for cancer and infectious disease treatment.
General Information
BounceWatch is an independent company data service, not affiliated with Mavupharma. To contact Mavupharma, visit mavupharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Mavupharma compare?
A PDF of Mavupharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Mavupharma soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Mavupharma
Business keywords: cancer treatment, infectious disease treatment, STING pathway modulators, drug development, precision medicine
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | $20.00M | 2 |
|
29 Nov 2017 |
Mavupharma Alternatives & Competitors
View All Alternatives
Dedicated to advancing cancer treatment through innovative MEK kinase inhibitors.
Innovative small molecule therapeutics for cancer and autoimmune disease treatment.
Pioneering targeted therapeutics to combat non-muscle invasive bladder cancer with precision.
FAQ About Mavupharma
Source: BounceWatch company record for Mavupharma, https://bouncewatch.com/company/mavupharma, updated 10 October 2024. When citing, please name BounceWatch and link this page.
